SRARP and sarcoma: In contrast, SRARP promoter methylation was significantly increased in cervical, head and neck, renal clear cell, renal papillary and thyroid cancers in addition to sarcoma and skin melanoma by 1.05‐ to 1.25‐fold (P < 0.005; Fig. 3B and Table S3).